Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. NTHI
9. SPY
10. EVMN

Go back to Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
(NASDAQ: GMAB) Delayed: 33.31 -0.22 (0.66%)
Previous Close $33.53    52 Week High $ 
Open $33.47    52 Week Low $ 
Day High $33.75    P/E N/A 
Day Low $33.22    EPS $ 
Volume 903,779